接受奥瑞利珠单抗或奥法木单抗治疗的多发性硬化患者治疗结局差异
这项前瞻性队列研究纳入2021年9月至2023年12月在德国3家三级中心开始奥瑞利珠单抗或奥法木单抗治疗的活动性复发型多发性硬化患者,随访至2024年6月,经倾向评分匹配后分析544例奥瑞利珠单抗与417例奥法木单抗患者。奥法木单抗在复发、残疾进展和MRI病灶累积方面不劣于奥瑞利珠单抗,亚组分析在初治和平台治疗患者中证实该结果;从S1P受体调节剂或那他珠单抗转换的患者中观察到的潜在差异需进一步验证。
要点
- 经倾向评分匹配后,奥法木单抗在复发、残疾进展和MRI病灶累积方面不劣于奥瑞利珠单抗。
- 初治和平台治疗患者的亚组分析证实了总体队列的非劣效结果。
- 从S1P受体调节剂或那他珠单抗转换的患者中观察到的潜在差异需进一步验证。
核心结论
- 在活动性复发型多发性硬化总体队列中,奥法木单抗在复发、残疾进展和MRI病灶累积方面不劣于奥瑞利珠单抗。
- 从S1P受体调节剂或那他珠单抗转换的患者中观察到的潜在差异需进一步验证。
研究设计与样本
- 前瞻性队列研究,纳入2021年9月至2023年12月开始奥瑞利珠单抗或奥法木单抗治疗的患者,随访至2024年6月。
- 招募自德国3家大型三级中心(杜塞尔多夫、埃森和吉森)。
- 初始入组1138例患者,经患者筛选和倾向评分匹配后,最终分析纳入544例奥瑞利珠单抗患者和417例奥法木单抗患者。
- 采用倾向评分匹配处理患者间的基线失衡。
- 评估临床复发、新发或扩大的MRI病灶以及6个月确认的残疾恶化;通过比较Kaplan-Meier估计值评价奥法木单抗相对奥瑞利珠单抗的非劣效性。
主要发现
- 主要分析中,奥法木单抗在复发、残疾进展和MRI病灶累积方面不劣于奥瑞利珠单抗。
- 亚组分析在初治和平台治疗患者中证实了上述发现。
- 从S1P受体调节剂或那他珠单抗转换的患者中可见奥法木单抗与奥瑞利珠单抗之间的潜在差异。
局限性
- 从S1P受体调节剂或那他珠单抗转换的患者中观察到的潜在差异需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: B-cell-depletion via CD20 antibodies is a safe and effective treatment for active relapsing multiple sclerosis (RMS). Both ocrelizumab (OCR) and ofatumumab (OFA) have demonstrated efficacy in randomized controlled trials and are approved for treatment of RMS, yet nothing is known on their comparative effectiveness, especially in the real-world setting. METHODS: This prospective cohort study includes patients that were started on either OCR or OFA between September 2021 and December 2023. Patients were followed until June 2024 and recruited at 3 large tertiary centers in Germany (Duesseldorf, Essen, and Giessen). Propensity-score-matching was used to address baseline imbalances among patients. Clinical relapses, presence of new or enlarging MRI lesions and 6-month confirmed disability worsening were evaluated. Non-inferiority of OFA compared to OCR was evaluated through comparison of Kaplan-Meier-estimates. RESULTS: A total of 1,138 patients were initially enrolled in the cohort. Following patient selection and propensity-score-matching, 544 OCR and 417 OFA patients were included in the final analysis. In our primary analysis, OFA was non-inferior to OCR in terms of relapses, disability progression, and accrual of MRI lesions. Subgroup analyses confirmed findings in previously naïve and platform-treated patients. Potential differences between OFA and OCR were seen in patients switching from S1P receptor modulators or natalizumab. CONCLUSION: We here provide comparative data on the effectiveness of OCR and OFA in patients with active RMS. OFA was non-inferior to OCR in the overall cohort. Potential differences observed in patients switching from S1P receptor modulators or natalizumab require further validation. ANN NEUROL 2025;97:583-595.
引用
- Meuth SG, Wolff S, Mück A, et al. Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab. Ann Neurol. 2024. PMID: 39582359. doi:10.1002/ana.27143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。